35 results about "Anti-Epidermal Growth Factor Receptor" patented technology

The disclosure provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.

The invention provides methods and compositions tor treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (BGKR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.

Human anti-epidermal growth factor receptor (EGFR) single-chain antibodies (scFvs) were isolated from a human IgM phage display library using purified epidermal growth factor receptor as antigen. Two isolates with different amino acid sequences were identified by ELISA as epidermal growth factor receptor-specific. The scFvs bind to the full length epidermal growth factor receptor and the truncated and / or mutated epidermal growth factor receptor on human cells. These anti-EGFR-scFvs are useful as therapeutic and / or diagnostic agents.

Disclosed are fully human anti-epidermal growth factor receptor (EGFR) antibodies, fragments thereof, and nucleic acid sequences encoding for the same. Further disclosed are methods of making and using the antibodies.

The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10−10 mol / L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.

The invention belongs to the field of pharmaceutical preparations, and relates to an injection preparation of a monoclonal antibody, in particular to an injection preparation of an anti-epithelial growth factor receptor (EGFR) monoclonal antibody. The present invention also relates to the use of the injection preparation for the preparation of drugs for the prevention and / or treatment of diseases related to EGFR activity disorders or disorders (such as tumors and / or tumor metastasis, diseases related to angiogenesis, non-specific inflammation) . The anti-EGFR monoclonal antibody injection preparation of the present invention exhibits good stability in tests such as shaking, 25°C and 40°C high-temperature accelerated tests, and 2-8°C long-term storage stability, and has good application prospects.

The invention discloses a preparation method of a novel cytokine fusion protein-chemokine interferon inducible protein 10 single-chain antibody (IP10-scFv). The method comprises the steps of: S1. synthesizing a human IP10 extracellular terminal gene; S2. utilizing a recombinant phage antibody system to construct the single-chain antibody of an anti-epidermal growth factor receptor mutant III (EGFRvIII); S3. conducting optimization synthesis on a (Gly4Ser)3 flexible joint; S4. cloning IP10 and the anti-EGFRvIII single-chain antibody into an eukaryotic expression vector, and conducting connection through the optimized (Gly4Ser)3 flexible joint, thus obtaining an IP10-scFv gene; and S5. subjecting the gene to high expression in Escherichia coli, thus obtaining IP10-scFv with biological activity. The IP10-scFv provided in the invention has a higher antigen-antibody binding rate, can reduce the dosage of IP10 clinically and reduce the toxic and side effects, and further can reduce the adoptive input amount of glioma specific cytotoxic T lymphocyte (CTL) and increase the activity of CTL.

The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular in the treatment of cancer.

The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10−10 mol / L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.

The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor receptor (EGFR) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an inhibitor of EGFR activity.

The present invention relates to the field of biotechnology, in particular to an anti-EGFR and anti-CD3 bispecific antibody and its application. The bispecific antibody of the present invention can specifically bind to tumor cell surface antigen epidermal growth factor receptor EGFR and immune cell surface antigen differentiation Cluster 3 is the CD3 molecule; wherein the single-chain antibody ScFv of the anti-CD3 antibody is located at the C-terminal of the constant region of the anti-EGFR antibody. The invention also provides the preparation method and clinical application of the bispecific antibody. The bispecific antibody of the present invention has high affinity and is used for treating tumor diseases caused by high or abnormal expression of EGFR and other diseases caused by overexpression of EGFR.

The invention discloses a kit for detecting B-raf gene polymorphism by a pyro-sequencing method and a method. By the kit, the B-raf gene rs113488022(V600E) single nucleotide polymorphism is detected. The kit comprises primers which are shown as SEQ ID NO.2-4. By the kit, the accurate, quick and high-throughout detection of B-raf gene mutation can be realized, so that the safe, reasonable and effective individual administration of a monoclonal antibody (such as cetuximab) of an anti-epidermal growth factor receptor, melanin inhibitor Zelboraf and the like can be realized.

The invention discloses an antibody, and a coding gene and application thereof. An amino acid sequence of a heavy chain variable region of the antibody is shown in the sequence 2 in a sequence table, while the amino acid sequence of a light chain is shown in the sequence 3 in the sequence table. Experimental results prove that the antibody of the invention has high binding activity (affinity is 2.7*10-8 mol / L) and high tumor cell growth and migration suppression capacity; and the affinity of an anti-epidermal growth factor receptor (EGFR) human-mouse chimeric antibody Cetuximab in foreign markets is 1.1*10-9 M. The humanized antibody of the invention can be better bound with an EGFR so as to ensure anti-tumor effect thereof. An anti-body preparation method of the invention has the advantage of simultaneously expressing the light chain and the heavy chain variable region. After all, the antibody and the preparation method thereof have vast application prospect in the field of the prevention and / or treatment of tumors.